Tempus AI Inc. stocks have been trading up by 6.61 percent after strong AI healthcare partnership news boosted investor optimism. Key Takeaways Piper Sandler upgraded Tempus AI to Overweight and lifted its price target to $76, leaning on the Personalis acquisition thesis and positive INTerpath-001

TEM price today is $65.08, with a live price change of 4.3932 in the last 24 hours. Convert, buy, sell and trade TEM on Bybit.

Discover how Tempus AI, Inc. • Robinhood Token (TEM) may perform from 2026 to 2031 using historical trends and forecasts. Buy, sell, and trade on Bybit today.

Tempus AI Inc. stocks have been trading up by 6.62 percent following upbeat coverage of its healthcare AI innovations. Key Takeaways Piper Sandler lifted its view on Tempus AI to Overweight and hiked the price target to $76 from $56, leaning on the Personalis deal and strong INTerpath-001 MRD data. The company is framed as…

Tempus AI's new whole genome push and why it matters to investors Tempus AI (TEM) is drawing fresh attention after announcing plans to build a research platform centered on 100,000 whole genomes, linked with detailed clinical histories and outcomes for AI driven disease research. Tempus AI has seen a sharp reset in sentiment, with a 1 day share price return of 5.42% and a 30 day share price return of 19.41%. However, the year to date share price return is slightly down 0.24% and the 1 year...

Tempus AI, Inc. is in focus after tempus launched an effort to build a large disease-specific whole-genome and clinical-outcomes dataset for AI-driven healthcare research, with attention on execution, demand, and the wider market setting.

Tempus AI received FDA 510(k) clearance for Tempus ECG-PH software. The tool analyzes standard 12-lead ECGs for pulmonary hypertension signs. It is the third FDA-cleared device in the company